BiotechTube

Ersodetug

Phase 3Recruiting
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tumor Hyperinsulinism (Tumor HI)

Conditions

Tumor Hyperinsulinism (Tumor HI)

Trial Timeline

Apr 16, 2025 → Sep 1, 2027

NCT ID
NCT06881992

About Ersodetug

Ersodetug is a phase 3 stage product being developed by Rezolute for Tumor Hyperinsulinism (Tumor HI). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06881992. Target conditions include Tumor Hyperinsulinism (Tumor HI).

What happened to similar drugs?

20 of 20 similar drugs in Tumor Hyperinsulinism (Tumor HI) were approved

Approved (20) Terminated (3) Active (0)
✅PexidartinibDaiichi SankyoApproved
✅KRN23Kyowa KirinApproved
✅DurvalumabAstraZenecaApproved
✅aprepitant + Dexamethasone and Ondansetron during CE-treatmentMerckApproved
✅Everolimus (RAD001)NovartisApproved
✅Chromogranin ANovartisApproved
✅Pasireotide + DiazoxideNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06881992Phase 3Recruiting

Competing Products

20 competing products in Tumor Hyperinsulinism (Tumor HI)

See all competitors
ProductCompanyStageHype Score
ALG.APV-527Alligator Bioscience ABPhase 1/2
18
ATOR-1017Alligator Bioscience ABPhase 1
19
ATOR-1015Alligator Bioscience ABPhase 1
19
mRNA-4359ModernaPhase 2
0
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-4106ModernaPhase 1
0
mRNA-4157 + Pembrolizumab + SoC TreatmentMerckPhase 1
33
mRNA-2416ModernaPhase 2
0
E7050EisaiPhase 1
29
FruquintinibHUTCHMEDPhase 1
23
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
BBP-398 + sotorasibBridgeBio PharmaPhase 1
18
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
18
CixutumumabEli LillyPhase 1
29
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
27
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
27